Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Coya Therapeutics (COYA) · oqro.io/stocks/COYA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Have Coya Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Coya Therapeutics was filed in the last 90 days. The latest on record was on Nov 14, 2024.
How often do Coya Therapeutics insiders buy and sell shares?
Since 2023, Coya Therapeutics insiders reported 12 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
Who is selling Coya Therapeutics stock?
No open-market sale by an insider of Coya Therapeutics (COYA) was filed with the SEC in the last 90 days.
Do members of Congress trade COYA?
No trade in Coya Therapeutics (COYA) was disclosed by a member of Congress in the last 12 months.
When does Coya Therapeutics report its next results?
Coya Therapeutics's next results are expected on Mar 15, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−50.7% (−$3.03) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $5.98 on Nov 20, 2025 to $2.95 on Nov 20, 2026 (−50.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$2$4$5$6$7$2.95
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Houston, Tx.
Last 12 months
−50.7%
S&P 500 +5.7% over the same dates
Market value
$70.8M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.41M shares sold short (5.9% of shares outstanding), +12.4% vs the previous count, 11.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$234K
−93.4% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $35.8M, at Sep 30, 2026
Net income, last 12 months
−$30.2M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Since the trade −56.7% · S&P 500 +16.3% · to Nov 20
The CFO of Coya Therapeutics paid $13K out of pocket for Coya Therapeutics shares. 2 other people at Coya Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Since the trade −59.8% · S&P 500 +15.2% · to Nov 20
Coya Therapeutics's Chief Medical Officer paid $20K out of pocket for Coya Therapeutics shares. 2 other people at Coya Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2023
Insiders of Coya Therapeutics reported 12 open-market purchases and 0 sales since 2023; purchases in 2 different years, most recently 2024.
Year
Bought
Sold
2024
$106K4×4 trades
—
2023
$3.6K8×8 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Coya Therapeutics over the 12 months to Nov 18, 2026: 1 clinical trial.
Owners above 5%
No Schedule 13D or 13G filing on COYA over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
When insiders usually buy
Last results
Nov 10, 2026
Within the 30 days after it, until Dec 10, 2026
Next results, expected
Mar 15, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Coya Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Coya Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
From “Overview”, in the company's words
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr. Shimon Sakaguchi. On October 6, 2025, Dr. Sakaguchi, along with two others, was awarded the Nobel Prize in Physiology or Medicine. Since Tregs were discovered, multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals.
What the section covers (30 headings)
Overview
Financings
Components of Results of Operations
Collaboration Revenue
Operating Expenses
Research and Development Expenses
In-Process Research and Development
General and Administrative Expenses
Depreciation
Other Income
Income Taxes
Results of Operations
For the Years Ended December 31, 2025 and 2024
Income Tax (Expense) Benefit
And 16 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 16, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Late-stage clinical trials
1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in amyotrophic lateral sclerosis (als). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Off-exchange trading: 50.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (13.5% on ATS, 36.8% with other brokers), close to its 26-week average of 48.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (12.8%), SIGMA X2 (10.0%), MS POOL (ATS-4) (9.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Contracts, lobbying and filings. ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Study of COYA 302 for the Treatment of ALS" (Phase 2/3, status active not recruiting), was updated on Oct 13, 2026, with primary completion listed for 2027-04. FINRA short interest for COYA on the settlement date of Oct 30, 2026 was 1,410,974 shares (+12.44% on the previous report), about 11.89 days of average volume. (Coya Therapeutics on OQRO)
Company reports, price and press. Coya Therapeutics filed a Form 8-K on Nov 10, 2026 (Item 2.02) that OQRO classes as: reported its results. Coya Therapeutics filed a Form 8-K on Aug 7, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Who holds it. 54 funds reported a stake in Coya Therapeutics in their 13F for Q2 2026. The largest by value: DME Capital Management, LP (30.1% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (10.8% of the value reported), Alyeska Investment Group, L.P. (10.3% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Study of COYA 302 for the Treatment of ALS" (Phase 2/3, status active not recruiting), was updated on Oct 13, 2026, with primary completion listed for 2027-04.
FINRA short interest for COYA on the settlement date of Oct 30, 2026 was 1,410,974 shares (+12.44% on the previous report), about 11.89 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Westwood Holdings Group Inc (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Coya Therapeutics filed a Form 8-K on Nov 10, 2026 (Item 2.02) that OQRO classes as: reported its results.
Coya Therapeutics filed a Form 8-K on Aug 7, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "This Amendment No. 1 to Current Report on Form 8-K/A (the ' Amendment ') amends the Current Report on Form 8-K of Coya Therapeutics, Inc. (the ' Company ') dated March 29, 2026 and filed with the Securities and Exchange Commissio..."
Coya Therapeutics filed a Form 8-K on Apr 2, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On March 29, 2026, Dr. Howard Berman resigned from the board of directors (the 'Board') of Coya Therapeutics, Inc. (the 'Company') and from his position as Executive Chairman, each effective as of April 1, 2026."
Press coverage listed by Finnhub: "Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update" (Yahoo, Nov 10, 2026).
Press coverage listed by Finnhub: "Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS" (Yahoo, Oct 14, 2026).
Press coverage listed by Finnhub: "Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference" (Yahoo, Oct 13, 2026).
COYA closed at $3.09 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $4.20 to $3.09, a change of −26.4%.
Who holds it
54 funds reported a stake in Coya Therapeutics in their 13F for Q2 2026. The largest by value: DME Capital Management, LP (30.1% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (10.8% of the value reported), Alyeska Investment Group, L.P. (10.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 19, 2025, COYA is down 49.1% and the index fund is up 4.1%: 53 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much COYA moves
A usual day
±2.2%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
10.0%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−13.1%Jan 15, 2026
Largest one-day rise
+15.9%May 14, 2026
Deepest fall of the year
−56.8%From the close of Nov 28, 2025 to Nov 5, 2026.
Days of 5% or more
44Out of 252 sessions, in either direction.
Beta 1.8(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Risk factors in the annual report
Latest annual report filed Mar 16, 2026, compared with the one filed Mar 18, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Disruptions at the FDA and other government agencies caused by shutdowns or funding shortages could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
Legal proceedings (Item 3)
From time to time, we may be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters and initiatives, negatively impacting our overall operations.
Source: SEC EDGAR, Form 10-K filed Mar 16, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.